AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers

PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND POTENTIALLY OTHER CANCERS AB8939 is a promising drug candidate for refractory AML, especially for cases with poor prognoses such as complex karyotypes, MECOM rearrangements, and TP53 mutations AB8939 has dual action against both proliferating tumor cells (via tubulin disruption) and q ...